Colorado

Five-Year Summary: July 2013 to June 2018

Tables and graphs report on cancer screening services provided through the program in a recent 5-year period. The data represent clinical services funded directly through the NBCCEDP as reported in the April 2019 submission of the NBCCEDP Minimum Data Elements (MDE).

National aggregate data are typically used to report results from the program and as a standard to compare results of grantee programs. Comparing data across grantee programs is not advised due to extensive variation across programs. For information on interpreting the data, refer to Screening Program Data. For information on the program, refer to About the Program.

Program Overview

Women Served through the NBCCEDP
Category Number
Women served [1] 24,341
Women screened [2] 24,030
Women receiving Pap tests 12,940
Women receiving mammography 16,243
Women receiving cervical cancer screening and diagnostic services 13,102
Women receiving breast cancer screening and diagnostic services 21,457

Each category reports counts of unduplicated women receiving services within the 5-year period. Women may be counted in more than one category.

1: Women served includes women receiving any NBCCEDP-funded screen or diagnostic procedure.

2: Women screened includes women receiving any NBCCEDP-funded screen (mammography, clinical breast exam, or Pap test).

Data source: April 2019 submission of NBCCEDP Minimum Data Elements (MDE) for Colorado.

Cervical Cancer Screening

This pie chart illustrates the distribution of 12,940 women receiving an NBCCEDP-funded Pap test from July 2013 to June 2018 by race and ethnicity.

This pie chart illustrates the distribution of 12,940 women receiving an NBCCEDP-funded Pap test from July 2013 to June 2018 by age.

Cervical Results and Outcomes
Category Number
Pap tests provided 13,709
Pap tests with abnormal results [1] 565
Percentage of Pap tests with abnormal results 4.1
Age-adjusted percentage [2] 3.7
Cervical cancers or premalignant cervical lesions [3] 492
CIN1 or LSIL 343
CIN2 or worse [4] 149
Rate of CIN2 or worse detected per 1,000 Pap tests [4] 10.9
Age-adjusted rate per 1,000 Pap tests [2] 10.9

1: Abnormals include Pap test results of: low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), atypical squamous cells of undetermined significance – cannot exclude HSIL (ASC-H), atypical glandular cells (AGC), and squamous cell cancer.

2: Adjusted to the age distribution of NBCCEDP participants having Pap tests performed in calendar year 2000.

3: Includes LSIL, HSIL, cervical intraepithelial neoplasia (CIN)1, CIN2, CIN3, carcinoma in situ (CIS), and invasive cervical cancer.

4: Includes HSIL, CIN2, CIN3, CIS, and invasive cervical cancer.

Table includes only NBCCEDP-funded Pap tests. An additional 54 women, not included above, were diagnosed with LSIL, HSIL, CIN1, CIN2, CIN3, CIS, or invasive cervical cancer through the NBCCEDP following a Pap test funded through another source.

Breast Cancer Screening

This pie chart illustrates the distribution of 16,243 women receiving an NBCCEDP-funded mammogram from July 2013 to June 2018 by race and ethnicity.

This pie chart illustrates the distribution of 16,243 women receiving an NBCCEDP-funded mammogram from July 2013 to June 2018 by age.

Breast Results and Outcomes
Category Number
Mammograms provided 20,417
Mammograms with abnormal results [1] 3,651
Percentage of mammograms with abnormal results 17.9
Age-adjusted percentage [2] 17.1
Breast cancers detected [3] 251
Rate of breast cancers detected per 1,000 mammograms 12.3
Age-adjusted rate per 1,000 mammograms [2] 12.1

1: Abnormals include mammogram results of: suspicious abnormality, highly suggestive of malignancy, and assessment incomplete (further imaging studies or film comparisons required).

2: Adjusted to the age distribution of NBCCEDP participants 40 years of age and older having mammograms performed in calendar year 2000.

3: Breast cancers include invasive breast cancer, ductal carcinoma in situ (DCIS), and other in situ excluding lobular carcinoma in situ (LCIS).

Table includes only NBCCEDP-funded mammograms provided to women age 40 and older. An additional 38 women, not included above, were diagnosed with CIS (other), DCIS, or invasive breast cancer through the NBCCEDP following a mammogram funded through another source.

Page last reviewed: October 15, 2019